Evaluation of polyethylene glycol modified adenovirus for innate response reduction and ligand specific cell targeting

dc.contributor.advisorBarry, Michael A.
dc.creatorMok, Hoyin Sunny
dc.date.accessioned2009-06-04T08:45:44Z
dc.date.available2009-06-04T08:45:44Z
dc.date.issued2005
dc.description.abstractClinical applications of adenoviruses as gene delivery vectors are limited by their propensity to invoke strong immune responses and toxicity. In addition, the inherent tropism of adenovirus prevents them from reaching the desired cell targets in vivo. This thesis evaluates the ability of chemically modified adenoviral vectors to evade innate immune responses, binding to blood cells, and to target specific cell types with cell-specific ligands. Previous studies have shown that polyethylene glycol (PEG) modification can protect vectors from pre-existing and adaptive immune responses by reducing protein-protein interactions. In this work, we have optimized PEGylation methods and have compared the induction of innate immune responses between modified and unmodified first generation and helper dependent adenoviruses in mouse models. The levels of interleukin-6, a cytokine induced during acute immune response, were found to be significantly lower in the most heavily PEGylated viruses in the murine models. We also observed that the uptake of PEG-modified vectors by macrophages and hepatic Kupffer cells were significantly reduced in vivo. Besides immunogenicity of the vectors, we also explored the binding affinity of chemically modified Ad to blood cells in vitro. PEG-modified Ad not only had reduced binding to erythrocytes and platelets, but also provoked reduced in vivo thrombocytopenia and prevented in vitro hemagglutination. To achieve clinically relevant gene transfer in cell types not susceptible to adenoviral transduction, we conjugated a wide array of cell-specific ligands onto adenoviruses via PEG crosslinkers to retarget the vectors to new receptors. Specifically, we conjugated epidermal growth factors (EGF) and anti-CD59 antibodies to Ad. Conjugation of these new ligands increased transduction on epidermal carcinoma and acute myeloid leukemia cell lines 5--10 fold over PEGylated vectors in vitro. However, the ability of targeted vectors to transduce cells varied greatly and is dependent on receptor densities, ligand functionality after conjugation and size of the conjugated vectors. Nonetheless, this strategy of incorporating cell-specific ligands to PEG modified adenovirus is valuable in creating a safer vector, thereby improving the overall safety and efficacy of adenoviral vectors for future cancer and metabolic disease gene therapy treatments.
dc.format.extent130 p.en_US
dc.format.mimetypeapplication/pdf
dc.identifier.callnoTHESIS BIOENG. 2005 MOK
dc.identifier.citationMok, Hoyin Sunny. "Evaluation of polyethylene glycol modified adenovirus for innate response reduction and ligand specific cell targeting." (2005) Diss., Rice University. <a href="https://hdl.handle.net/1911/18784">https://hdl.handle.net/1911/18784</a>.
dc.identifier.urihttps://hdl.handle.net/1911/18784
dc.language.isoeng
dc.rightsCopyright is held by the author, unless otherwise indicated. Permission to reuse, publish, or reproduce the work beyond the bounds of fair use or other exemptions to copyright law must be obtained from the copyright holder.
dc.subjectBiomedical engineering
dc.titleEvaluation of polyethylene glycol modified adenovirus for innate response reduction and ligand specific cell targeting
dc.typeThesis
dc.type.materialText
thesis.degree.departmentBioengineering
thesis.degree.disciplineEngineering
thesis.degree.grantorRice University
thesis.degree.levelDoctoral
thesis.degree.nameDoctor of Philosophy
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
3168106.PDF
Size:
9.44 MB
Format:
Adobe Portable Document Format